A phase 1b study of poziotinib in combination with T-DM1 in women with advanced or metastatic HER2-positive breast cancer

被引：0
|
作者：
Bhat, G.
Potter, D.
Bharadwaj, J.
Khan, N.
Shabazz, L.
Tache, J.
Yang, Z.
机构：
[1] Spectrum Pharmaceut, Irvine, CA USA
[2] Univ Minnesota, Minneapolis, MN USA
[3] Pacific Canc Med Ctr, Anaheim, CA USA
[4] Delta Hematol Oncol Associates, Portsmouth, VA USA
[5] BRCR Med Ctr, Plantation, FL USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS18-OT2-07-04
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT2-07-04
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Efficacy of T-DM1 in patients with HER2-positive metastatic breast cancer previously treated with pertuzumab
    Matsui, K.
    Yoshikawa, A.
    Oyama, K.
    Nozaki, Z.
    Tanada, Y.
    Earashi, M.
    Kiyohara, K.
    Nagata, T.
    Fukushima, W.
    Shimizu, T.
    Maeda, K.
    ANNALS OF ONCOLOGY, 2017, 28
  • [22] Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer
    Dan Lu
    Chunze Li
    Matthew Riggs
    Daniel Polhamus
    Jonathan French
    Priya Agarwal
    Shang-Chiung Chen
    Shweta Vadhavkar
    Monika Patre
    Alexander Strasak
    Angelica Quartino
    Jin Yan Jin
    Sandhya Girish
    Cancer Chemotherapy and Pharmacology, 2019, 84 : 175 - 185
  • [23] Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer
    Lu, Dan
    Li, Chunze
    Riggs, Matthew
    Polhamus, Daniel
    French, Jonathan
    Agarwal, Priya
    Chen, Shang-Chiung
    Vadhavkar, Shweta
    Patre, Monika
    Strasak, Alexander
    Quartino, Angelica
    Jin, Jin Yan
    Girish, Sandhya
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (01) : 175 - 185
  • [24] Clinical efficacy and safety of T-DM1 for patients with HER2-positive breast cancer
    Ma, Bo
    Ma, Qianqian
    Wang, Hongqiang
    Zhang, Guolei
    Zhang, Huiying
    Wang, Xiaohong
    ONCOTARGETS AND THERAPY, 2016, 9 : 959 - 976
  • [25] Pertuzumab and T-DM1: New perspectives in the treatment of HER2-positive breast cancer
    Guiu, S.
    Fumoleau, P.
    ONCOLOGIE, 2015, 17 (5-6) : 263 - 270
  • [26] RESPONSE TO T-DM1 IN HER2-POSITIVE BREAST CANCER BRAIN METASTASES (BM)
    Berghoff, A. S.
    Bartsch, R.
    Bergen, E.
    Rudas, M.
    Gnant, M.
    Dieckmann, K.
    Pinker, K.
    Zielinski, C. C.
    Steger, G. G.
    Preusser, M.
    NEURO-ONCOLOGY, 2014, 16
  • [27] Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
    Hunter, Francis W.
    Barker, Hilary R.
    Lipert, Barbara
    Rothe, Francoise
    Gebhart, Geraldine
    Piccart-Gebhart, Martine J.
    Sotiriou, Christos
    Jamieson, Stephen M. F.
    BRITISH JOURNAL OF CANCER, 2020, 122 (05) : 603 - 612
  • [28] Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer
    Francis W. Hunter
    Hilary R. Barker
    Barbara Lipert
    Françoise Rothé
    Géraldine Gebhart
    Martine J. Piccart-Gebhart
    Christos Sotiriou
    Stephen M. F. Jamieson
    British Journal of Cancer, 2020, 122 : 603 - 612
  • [29] Impact of trastuzumab emtansine (T-DM1) on spleen volume in patients with HER2-positive metastatic breast cancer
    Akyildiz, Arif
    Ismayilov, Rashad
    Abdurrahimli, Najmaddin
    Ormanci, Aylin
    Guven, Deniz Can
    Tuncel, Murat
    Onur, Mehmet Ruhi
    Aksoy, Sercan
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2024, 55 (02) : 100 - 105
  • [30] T-DM1 as a New Treatment Option for Patients with Metastatic HER2-positive Breast Cancer in Clinical Practice
    Michel, Laura L.
    Bermejo, Justo Lorenzo
    Gondos, Adam
    Marme, Frederik
    Schneeweiss, Andreas
    ANTICANCER RESEARCH, 2015, 35 (09) : 5085 - 5090
12345